Exelixis Inc. has announced a collaboration with Natera to conduct the STELLAR-316 Phase 3 pivotal trial, which will evaluate Exelixis' oral kinase inhibitor, zanzalintinib, with and without an immune checkpoint inhibitor in patients with resected stage II/III colorectal cancer. Natera's Signatera™ test will be used to identify patients with molecular residual disease (MRD) and for ongoing monitoring of circulating tumor DNA clearance throughout the trial. Exelixis expects to initiate enrollment for the STELLAR-316 trial in mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exelixis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260107329077) on January 07, 2026, and is solely responsible for the information contained therein.